ArticleSignal transduction and targeted therapy2026
MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth.
Abstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma.International journal of molecular sciences · 2026Review
- Immunosuppressive cells as barriers to cancer therapy: mechanisms and emerging solutions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Aloña Agirre-LizasoDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.ORCID http://orcid.org/0000-0003-2971-1423
Maider Huici-IzagirreDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Colm J O'RourkeBiotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ekaterina ZhuravlevaBiotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Guido CarpinoDepartment of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0001-8570-2519
Diletta OveriDepartment of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0003-3561-8903
Josu Urretabizkaia-GarmendiaDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Ibone LabianoDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Ana KorosecInstitute for Vascular Biology, Centre for Physiology and Pharmacology, Medical University Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-6551-6727
Beatriz ValDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Diego F CalvisiInstitute of Pathology, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-6038-8567
Sumera I IlyasDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-2709-3003
Joke M M den HaanDepartment of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-4421-6917
Patricia AspichuetaCIBERehd, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-3553-1755
Elizabeth HijonaDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Adelaida La CastaDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Raúl Jiménez-AgüeroDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Ana LleoDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.ORCID http://orcid.org/0000-0002-0561-7902
Rocio I R MaciasCIBERehd, Instituto de Salud Carlos III (ISCIII), Madrid, Spain.ORCID http://orcid.org/0000-0002-4748-0326
Eugenio GaudioDepartment of Anatomical, Histological, Forensic Medicine and Orthopedic Sciences, Sapienza University of Rome, Rome, Italy.
European CCA Histology Registry
Jesper B AndersenBiotech Research and Innovation Centre (BRIC), Department of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-1760-5244
Gernot SchabbauerInstitute for Vascular Biology, Centre for Physiology and Pharmacology, Medical University Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0002-7490-8009
Luis BujandaDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.ORCID http://orcid.org/0000-0002-4353-9968
Pedro M RodriguesDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain.ORCID http://orcid.org/0000-0001-6193-7436
Omar SharifInstitute for Vascular Biology, Centre for Physiology and Pharmacology, Medical University Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0001-7899-2343
Jesus M Banales *Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain. jesusmaria.banalesasurmendi@bio-gipuzkoa.eus.ORCID http://orcid.org/0000-0002-5224-2373
Maria J Perugorria *Department of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute - Donostia University Hospital -, University of the Basque Country (UPV/EHU), San Sebastian, Spain. majesus.perugorriamontiel@bio-gipuzkoa.eus.ORCID http://orcid.org/0000-0002-7636-0972
Funding
Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 2024 - 30653Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) FWF-P35168Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza (Department of Industry, Innovation, Trade and Tourism, Basque Government) KK-2020/00008Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza (Department of Industry, Innovation, Trade and Tourism, Basque Government) KK-2023/00099Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza (Department of Industry, Innovation, Trade and Tourism, Basque Government) KK-2025/00031Eusko Jaurlaritza (Basque Government) IT1476-22Eusko Jaurlaritza (Basque Government) IT1761-22Eusko Jaurlaritza (Basque Government) PRE_2016_1_0152Eusko Jaurlaritza (Basque Government) PRE_2018_1_0184Eusko Jaurlaritza (Basque Government) PRE_2023_1_0349Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CP22/00073Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) CPII19/00008Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI20/00186Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI20/00189Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI21/00922Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI23/00681Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI23/01565Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI23/01850Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI24/00148Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2019111024Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2019222054Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2020333010Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2021111021Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2021333003Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2022111070Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2022333032Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2023111017Osasun Saila, Eusko Jaurlaritzako (Departamento de Salud, Gobierno Vasco) 2023333005
Abstract
Cholangiocarcinoma (CCA) comprises a heterogeneous group of biliary malignant tumors with poor prognosis and limited therapeutic options. Recent studies have highlighted the role of the immune system in the development and progression of intrahepatic CCA (iCCA). In this study, we investigated the role of the scavenger receptor MARCO in iCCA. Employing transcriptomic, spatial proteomic and histological analyses of human samples, MARCO was found on a specific subtype of tumor-associated macrophages linked to immunosuppression and extracellular matrix remodeling within the tumor microenvironment. High MARCO expression in human iCCA tumors correlated with worse overall survival, T cell dysfunction and increased collagen deposition. In line with this, MARCO expression was associated with a T
Indexed as
Bile Duct NeoplasmsCarcinogenesisCholangiocarcinomaReceptors, ImmunologicAnimalsGene Expression Regulation, NeoplasticHumansImmunosuppression TherapyMacrophagesMiceMice, KnockoutTumor MicroenvironmentMARCO protein, humanMarco protein, mouseReceptors, Immunologic
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.